Goserelin information

Goserelin
Clinical data
Trade names	Zoladex, others
Other names	D-Ser(But)6Azgly10-GnRH
AHFS/Drugs.com	Monograph
MedlinePlus	a601002
Pregnancy; category	D (3.6mg) / X (10.8mg) (USA);
Routes of; administration	Implant
Drug class	GnRH analogue; GnRH agonist; Antigonadotropin
ATC code	L02AE03 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	27.3%
Elimination half-life	4–5 hours
Identifiers
	IUPAC name N-(21-((1H-indol-3-yl)methyl)-1,1-diamino-12-(tert-butoxymethyl)-6-(2-(2-carbamoylhydrazinecarbonyl)cyclopentanecarbonyl)-15-(4-hydroxybenzyl)-18-(hydroxymethyl)-25-(1H-imidazol-5-yl)-9-isobutyl-8,11,14,17,20,23-hexaoxo-2,7,10,13,16,19,22-heptaazapentacos-1-en-24-yl)-5-oxopyrrolidine-2-carboxamide;
CAS Number	65807-02-5 ;
PubChem CID	5311128;
IUPHAR/BPS	3879;
DrugBank	DB00014 ;
ChemSpider	4470656 ;
UNII	0F65R8P09N;
KEGG	D04405 ;
ChEBI	CHEBI:5523 ;
ChEMBL	ChEMBL1201247 ;
CompTox Dashboard (EPA)	DTXSID7048297 ;
ECHA InfoCard	100.212.024
Chemical and physical data
Formula	C59H84N18O14
Molar mass	1269.433 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O;
	InChI InChI=1S/C59H84N18O14/c1-31(2)22-40(49(82)68-39(12-8-20-64-57(60)61)56(89)77-21-9-13-46(77)55(88)75-76-58(62)90)69-54(87)45(29-91-59(3,4)5)74-50(83)41(23-32-14-16-35(79)17-15-32)70-53(86)44(28-78)73-51(84)42(24-33-26-65-37-11-7-6-10-36(33)37)71-52(85)43(25-34-27-63-30-66-34)72-48(81)38-18-19-47(80)67-38/h6-7,10-11,14-17,26-27,30-31,38-46,65,78-79H,8-9,12-13,18-25,28-29H2,1-5H3,(H,63,66)(H,67,80)(H,68,82)(H,69,87)(H,70,86)(H,71,85)(H,72,81)(H,73,84)(H,74,83)(H,75,88)(H4,60,61,64)(H3,62,76,90)/t38-,39-,40-,41-,42-,43-,44-,45+,46-/m0/s1 ; Key:BLCLNMBMMGCOAS-URPVMXJPSA-N ;
	(what is this?) (verify)

Goserelin, sold under the brand name Zoladex among others, is a medication which is used to suppress production of the sex hormones (testosterone and estrogen), particularly in the treatment of breast and prostate cancer.^[1]^[2] It is an injectable gonadotropin releasing hormone agonist (GnRH agonist).

Structurally, it is a decapeptide. It is the natural GnRH decapeptide with two substitutions to inhibit rapid degradation.

Goserelin stimulates the production of the sex hormones testosterone and estrogen in a non-pulsatile (non-physiological) manner. This causes the disruption of the endogenous hormonal feedback systems, resulting in the down-regulation of testosterone and estrogen production.

It was patented in 1976 and approved for medical use in 1987.^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

^ Dictionary of Organic Compounds. CRC Press. 1996. pp. 3372–. ISBN 978-0-412-54090-5.
^ Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 136–. ISBN 978-94-011-4439-1.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 9783527607495.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[CRCPress-1] Dictionary of Organic Compounds. CRC Press. 1996. pp. 3372–. ISBN 978-0-412-54090-5.

[MortonHall2012-2] Morton IK, Hall JM (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 136–. ISBN 978-94-011-4439-1.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 514. ISBN 9783527607495.

[WHO22nd-4] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

Goserelin information

and 24 Related for: Goserelin information

Goserelin

Superagonist

Subcutaneous administration

WHO Model List of Essential Medicines

Estrogen

List of antiandrogens

Menstrual cycle

Luteinizing hormone

Omeprazole

Breast cancer

Rosuvastatin

AstraZeneca

Quetiapine

Prostate

Leuprorelin

Human chorionic gonadotropin

Orchiectomy

Propofol

Gonadorelin

Dapagliflozin

Isosorbide mononitrate

Metoprolol

Pascal Soriot

Prostate cancer